Autolus Therapeutics plc (NASDAQ:AUTL) headquartered in London, will host a conference call for the investment community to discuss the 3Q20 earnings result on 5th November 2020 at 8:30 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.autolus.com
Earnings Expectation
Autolus Therapeutics plc is reporting third quarter earnings results on Thursday 5th November 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.71 per share from $ 0.30 million in revenue. For the full year, analysts predict revenues of $ 1.14 million, while looking forward to loss of $ 2.7 per share.
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.
